uniQure/CSL’s EtranaDez Could Take Lead Position In Hemophilia B Gene Therapy Market

The therapy could also face competition from players like Freeline, but new Phase III data position uniQure and CSL Behring well for planned FDA and EMA filings.

3-D Rendering Red Blood Cells
uniQure and CSL Behring announced positive Phase III data for EtranaDez in hemophilia B • Source: Shutterstock

After a delay in their original filing plans, uniQure N.V. and CSL Limited (CSL Behring) have come back with Phase III data on etranacogene dezaparvovec (EtranaDez) in hemophilia B that should be sufficient to seek US Food and Drug Administration approval for the gene therapy in the first half of 2022, in addition to opening up a significant commercial opportunity.

The companies said on 9 December that the HOPE-B trial met the primary endpoint of non-inferiority in annualized bleeding rate...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Gene Therapies

More from Advanced Therapies